Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84977 | 0.83 | HTR1A (0.41) | HTR1AHTR7TNKSTNKS2ALDH1A1 | |
| SCHEMBL84513 | 0.83 | HTR1A (0.41) | HTR1AHTR7TNKSTNKS2ALDH1A1 | |
| SCHEMBL15435659 | 0.76 | HTR1A (0.37) | HTR1AHTR7TNKSTNKS2ALDH1A1 | |
| SCHEMBL85057 | 0.75 | HTR1A (0.40) | HTR1AHTR7TNKSTNKS2ALDH1A1 | |
| SCHEMBL91609 | 0.73 | HTR1A (0.40) | HTR1AHTR7TNKSTNKS2ALDH1A1 | |
| SCHEMBL70462 | 0.73 | HTR1A (0.41) | HTR1AHTR7TNKSTNKS2ALDH1A1 | |
| SCHEMBL69730 | 0.72 | HTR1A (0.40) | HTR1AHTR7TNKSTNKS2ALDH1A1 | |
| SCHEMBL68684 | 0.69 | HTR1A (0.40) | HTR1AHTR7TNKSTNKS2ALDH1A1 | |
| SCHEMBL15435583 | 0.69 | HTR1A (0.37) | HTR1AHTR7TNKSTNKS2ALDH1A1 | |
| SCHEMBL70516 | 0.68 | HTR1A (0.39) | HTR1AHTR7TNKSTNKS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129397-B2 | Substituted thieno[2,3-d]pyrimidines as AMPA modulators | MSD OSS B.V. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090131455-A1 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131455-A1 | HETEROCYCLIC DERIVATIVES | GRIN2C, GRIK5, GRIN1 | HTR1A 135/4885HTR7 124/4885TNKS 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.